A clinical formulation indicated for Antivirals. This therapy assists with the disruption of viral replication pathways to promote reduced viral load levels.
Indicated to address chronic Hepatitis C by targeting viral replication complexes to alleviate systemic infection and support improved liver health and long-term recovery outcomes.
Mechanism of Action
Daclatasvir inhibits the NS5A protein, a key part of the virus's replication machinery. By blocking this protein, it prevents the virus from assembling new particles and replicating its genetic material.
Route of Administration
Oral
Onset Time
Steady state in 3 days
Duration
24 hours
Contraindications
Strong CYP3A inducers, Hypersensitivity to daclatasvir, Severe liver impairment (uncompensated)
Severe Adverse Events
Bradycardia (with Amiodarone), Hepatitis B reactivation, Liver failure, Severe allergic reactions, Cardiac rhythm disorders
Information for Daclatasvir is sourced from established medical standards and updated frequently. It is provided for general reference and should be confirmed with a healthcare professional before use.
